178 related articles for article (PubMed ID: 24216166)
1. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.
Yazbeck VY; Li C; Grandis JR; Zang Y; Johnson DE
Oral Oncol; 2014 Feb; 50(2):120-7. PubMed ID: 24216166
[TBL] [Abstract][Full Text] [Related]
2. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.
Li R; Boehm AL; Miranda MB; Shangary S; Grandis JR; Johnson DE
Neoplasia; 2007 Oct; 9(10):801-11. PubMed ID: 17971900
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Okumura K; Sinicrope FA
Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
[TBL] [Abstract][Full Text] [Related]
4. GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.
Cournoyer S; Addioui A; Belounis A; Beaunoyer M; Nyalendo C; Le Gall R; Teira P; Haddad E; Vassal G; Sartelet H
BMC Cancer; 2019 Oct; 19(1):1018. PubMed ID: 31664947
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
[TBL] [Abstract][Full Text] [Related]
7. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H
BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
Clin Cancer Res; 2012 Oct; 18(20):5639-49. PubMed ID: 22929803
[TBL] [Abstract][Full Text] [Related]
11. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043
[TBL] [Abstract][Full Text] [Related]
12. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA
Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880
[TBL] [Abstract][Full Text] [Related]
13. Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells.
Wang G; Chen S; Edwards H; Cui X; Cui L; Ge Y
Oncol Rep; 2014 Dec; 32(6):2789-94. PubMed ID: 25333301
[TBL] [Abstract][Full Text] [Related]
14. Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.
Steele TM; Talbott GC; Sam A; Tepper CG; Ghosh PM; Vinall RL
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875757
[TBL] [Abstract][Full Text] [Related]
15. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy.
Heidari N; Hicks MA; Harada H
Cell Death Dis; 2010 Sep; 1(9):e76. PubMed ID: 21364679
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Mihara M; Shintani S; Kiyota A; Matsumura T; Wong DT
Int J Oncol; 2002 Jul; 21(1):95-101. PubMed ID: 12063555
[TBL] [Abstract][Full Text] [Related]
17. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
[TBL] [Abstract][Full Text] [Related]
19. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
20. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Zerp SF; Stoter TR; Hoebers FJ; van den Brekel MW; Dubbelman R; Kuipers GK; Lafleur MV; Slotman BJ; Verheij M
Radiat Oncol; 2015 Jul; 10():158. PubMed ID: 26223311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]